When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Mahon, F.-X.
Clinical Advances in Hematology and Oncology H&o 17(2): 101-103
2019
ISSN/ISBN: 1543-0790 PMID: 30845112 Document Number: 698104
Document emailed within 1 workday
Related Documents
Dou, X.L.; Wang, S.S.; Fang, J.L.; Yu, L.; Ren, X.; Huang, X.J.; Jiang, Q. 2018: Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia Zhonghua Nei Ke Za Zhi 57(9): 649-655Bagadi, S.; Saikia, T.; Pany, A.; Das, B. 2011: Analysis of ABL Kinase Domain Mutations Conferring Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Cases from India Clinical Laboratory 57(7-8): 619-623
Turkina, A.G.; Domracheva, E.V.; Vorontsova, A.V.; Aseeva, E.A.; Vinogradova, O.I.; Stakhina, O.V.; Gusarova, G.A.; Diagileva, O.A.; Semenova, E.A.; Vakhrusheva, M.V.; Kolosheĭnova, T.I.; Abakumov, E.M.; Chelysheva, E.I.; Goriacheva, S.R.; Ivanova, T.V.; Zakharova, E.S.; Kolosova, L.I.; Zakharova, A.V.; Naumova, I.N.; Diachenko, L.V.; Kulikov, S.M.; Kovaleva, L.G.; Khoroshko, N.D. 2009: Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases Terapevticheskii Arkhiv 81(7): 29-36
Bhatia, R.; Munthe, H.A.; Verfaillie, C.M. 1998: Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors Leukemia 12(11): 1708-1717
Haidary, A.M.; Azma, R.Z.; Ithnin, A.; Alauddin, H.; Tumian, N.R.; Tamil, A.M.; Razak, N.F.A.; Abu Amis, S.H.; Zin, N.M.; Shuib, S. 2019: FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy Malaysian Journal of Pathology 41(2): 149-160
Filanovskaia, L.I.; Togo, A.V.; Shcherbakova, E.G.; Blinov, M.N. 1994: Thymidine kinase activity in leukocytes from patients with chronic myeloid leukemia at various periods in the disease Voprosy Meditsinskoi Khimii 40(1): 29-32
Ohno, R. 2001: Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor Nihon Rinsho. Japanese Journal of Clinical Medicine 59(12): 2389-2394
Przytulska, J.; Tupikowski, K.; Bednarek-Tupikowska, G. 2014: Thyroid dysfunction in patients treated with tyrosine kinase inhibitors Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 36(211): 42-44
Wong, M.; Sade, S.; Gilbert, M.; Klieb, H.B.E. 2011: Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature Dermatology Online Journal 17(5): 4
Meloni, G.; Russo, D.; Baccarani, M.; Testoni, N.; Martinelli, G.; Fanin, R.; Zuffa, E.; Rosti, G.; Alimena, G.; Saglio, G.; Mandelli, F.; Tura, S. 1999: A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. the Italian Co-operative Study Group on Chronic Myeloid Leukemia Haematologica 84(8): 707-715
Levy, B.P.; Rao, P.; Becker, D.J.; Becker, K. 2016: Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors Oncology 30(7): 601-612
Cannistra, S.A.; Groshek, P.; Griffin, J.D. 1989: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia Leukemia 3(5): 328-334
Baccarani, M. 1998: SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768 Leukemia 12(7): 1168-1170
Goldman, J. 2004: CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology 10(3): 181-184
Pang, S.H.; Guo, Z.R.; Liang, X.T. 1997: Synthesis and biological activity of tyrosine protein kinase inhibitors Yao Xue Xue Bao 32(7): 515-523
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Reid, T-Elinor.; Fortunak, J.M.; Wutoh, A.; Simon Wang, X. 2016: Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors Current Topics in Medicinal Chemistry 16(13): 1452-1462
Frassoni, F.; Martinelli, G.; Saglio, G.; Sessarego, M.; Podestà, M.; Piaggio, G.; Farabegoli, P.; Zaccaria, A.; Testoni, N.; Remiddi, C. 1995: bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase Bone Marrow Transplantation 16(4): 595-601
Sheng, J.Z.; Wong, N.S.; Wang, H.X.; Wong, T.M. 1997: Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytes American Journal of Physiology 272(2 Pt 1): C560-C564
Jiang, J.-f.; Chen, X.-y.; Zhong, D.-f. 2016: Metabolic research of domestically developed small molecule tyrosine kinase inhibitors Yao Xue Xue Bao 51(2): 248-256